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Although tumour stage and nodal status are established prognostic factors for resectable gastric cancer, the relative importance
of other pathological characteristics remains unclear. This study reports univariate and multivariate analyses of the prognostic
value of various pathological and staging factors based on 324 patients entered into the MRC randomised surgical trial for gastric
cancer. In the univariate analysis tumour stage, nodal status, UICC clinical stage, number of involved nodes, WHO predominant
type, mixed Lauren type, Ming type, tumour differentiation, lymphocytic and tumour stromal eosinophilic inﬁltration were all
found to have a signiﬁcant impact on survival (logrank test, 5% level). In the multivariate analysis, UICC clinical stage and
eosinophilic inﬁltration were found to have a signiﬁcant inﬂuence. Risk of death increased for UICC stage II and III patients
(Hazard Ratio for stage II compared to stage I=2.0, 95% Conﬁdence Interval (CI) 1.4–2.9; Hazard Ratio for stage III compared
to stage I=3.5, 95% CI 2.5–4.8). Patients with numerous eosinophils had a lower risk of death than those with none (Hazard
Ratio=0.5, 95% CI 0.3–0.8). This association between survival and eosinophilic inﬁltration merits further study.
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Carcinoma of the stomach isa majorcause of death within the United
Kingdom. The only proven effective therapy remains surgical resec-
tion though overall 5-year survival rates remain poor. In the 1980s,
results from Japan suggested that gastrectomy with radical lymphade-
nectomy (D2 resection) improved survival over the standard D1
resection (Maruyama et al, 1987). Some Western centres practised
and reported favourably on D2 resections (Sue-Ling et al, 1993) but
the superiority of these operations was not tested prospectively until
the launch of the Medical Research Council Gastric Cancer Surgical
Trial (ST01) in 1986. In this prospective randomized study, D1 resec-
tion (removal of regional perigastric nodes) was compared with D2
resection (extended lymphadenectomy to include level 1 and 2 regio-
nal nodes). Central randomization followed staging laparotomy. Of
737 patients with histologically proven gastric adenocarcinoma regis-
tered, 337 were ineligible at staging laparotomy because of advanced
disease and 400 were randomised.
The preliminary results of ST01 (Cuschieri et al, 1996) and a
similar Dutch trial (Bonenkamp et al, 1995) had documented high-
er post-operative mortality and morbidity for patients randomised
to D2 resection. This was thought to be a consequence of distal
pancreatectomy and splenectomy, which were an integral part of
most D2 procedures when these trials were designed. Long-term
results of both trials have since failed to show a signiﬁcant survival
beneﬁt to D2 surgery (Bonenkamp et al, 1999; Cuschieri et al,
1999).
An important aspect of ST01 was a full examination of all
resected tumours by the pathology review panel. As well as deter-
mining tumour stage and nodal status, tumours were assessed
using the WHO, Lauren, Mulligan and Ming classiﬁcations, in
addition to grading based on the degree of differentiation. Extent
of inﬁltration of the tumour stroma by lymphocytes and eosino-
phils was also assessed as some studies had suggested a potential
survival beneﬁt for patients with marked stromal inﬁltrates (Yu
et al, 1995; Songun et al, 1996). The effect of these pathological
and staging criteria on patient survival is examined in this study.
MATERIALS AND METHODS
Patients
Patients enrolled in MRC ST01 were to have had histologically
proven and potentially curable gastric carcinoma. They were
excluded if they were young (520 years), had undergone previous
gastric surgery, harboured a coexisting cancer or had serious co-
morbid cardiorespiratory disease that precluded a safe D2 resection.
All patients underwent staging laparotomy to deﬁne potentially
curative disease. Eligible cases were those that fell within the Japa-
nese gastric cancer stages I–III except those with positive infracolic
aortic nodes. Within the same operating session patients were
randomized centrally to receive either D1 or D2 surgery.
Pathology
Pathologists at each local centre provided information on the size,
differentiation and extent of the tumour, and on nodal groups. In
addition a panel of specialist gastrointestinal pathologists reviewed
the tumours. In this analysis, all staging criteria were deﬁned using
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was assessed at pathology review. Nodal status and number of
involved nodes were determined using information on nodal exam-
ination undertaken by local pathologists. These measurements were
combined to give an overall clinical stage.
The review pathologists graded the tumours as well, moderately
or poorly differentiated, and also assessed them using the WHO,
Lauren, Mulligan and Ming classiﬁcations (Mulligan and Rember,
1954; Lauren, 1965; Ming, 1977; Watanabe et al, 1990). Eosinophi-
lic and lymphocytic inﬁltration in the stroma of the tumour were
also determined. The staining used for this purpose was a standard
H&E and the microscope used for the study was a Zeiss Axioplan.
A ‘high power ﬁeld’ on this microscope (i.e., using a 640 objec-
tive) measures 0.6 mm in diameter on the slide, giving an area
of 1.88 mm
2. The number of stromal eosinophils was recorded
as ‘numerous’ (an average of ﬁve or more eosinophils in 10 such
high power microscopic ﬁelds (HPFs)), ‘scanty’ (an average of less
than ﬁve eosinophils in 10 HPFs) or ‘absent’ (no eosinophils
present). Stromal lymphocytic inﬁltration was graded as ‘unre-
markable’ or ‘heavy inﬁltrate’.
In total, 400 eligible patients were randomised into this trial.
Local pathology data was collected for 386 patients. Due to logis-
tical difﬁculties, only one reference pathologist (IC Talbot) was
able to review the majority of the tumour slides (the other three
pathologists were able to review only 8, 24 and 48% of the materi-
al). Using Talbot’s assessments (carried out blind of the clinical
outcome), complete prognostic information was available for 324
patients (154 D1, 170 D2). These form the basis of the present
analyses.
Patients were followed up at regular intervals. For the patients
within this analysis, follow-up is available to death or 3 years in
98% of patients and the median follow-up time is 8 years. Patients
were followed up through the participating clinician, their GP or
via the Ofﬁce for National Statistics.
Statistical methods
The statistical analysis was conducted using the SPSS software
system. The primary endpoint of this analysis is survival, calculated
from date of surgery. The univariate survival analyses were
performed using the Kaplan–Meier method, and treatment
comparisons were made via the log-rank test. Cox’s proportional
hazards technique was used to ﬁt the multivariate survival model,
signiﬁcant prognostic factors were chosen using a forward condi-
tional stepwise method. Categorical variables were ﬁtted using
dummy variables in the multivariate model, for ordinal variables
the lowest value was used for reference. A signiﬁcance level of
5% was adopted for all analyses. No signiﬁcant difference in survi-
val between D1 and D2 surgery was found for this trial so it was
considered reasonable to combine the treatment arms for the
purposes of this analysis.
C
l
i
n
i
c
a
l
Table 1 Patient characteristics at randomization
D1 surgery D2 surgery Total
n (%) n (%) n (%)
Sex
Male 102 (66) 120 (71) 222 (69)
Female 52 (34) 50 (29) 102 (31)
Age
560 36 (23) 43 (25) 79 (24)
60–69 60 (39) 54 (32) 114 (35)
70+ 58 (38) 73 (43) 131 (41)
Location
C, CM 51 (33) 52 (31) 103 (32)
M, MC, MA 23 (15) 37 (22) 60 (19)
A, AM 72 (47) 78 (46) 150 (46)
CMA 8 (5) 3 (2) 11 (3)
Spleen or pancreas removed?
Neither removed 103 (67) 55 (32) 158 (49)
Spleen removed 44 (29) 15 (9) 59 (18)
Both removed 7 (5) 100 (59) 107 (33)
Total 154 170 324
Table 2 Survival estimates for each prognostic variable
5-year
survival Log-rank
Count rate (%) statistic d.f. P-value
Tumour stage
T1 53 69
T2 125 32
T3 146 14 44.46 1* 50.0001
Nodal stage
N0 118 53
N1 124 19
N2 82 14 37.27 1* 50.0001
Clinical stage
I 103 60
II 81 26
III 140 10 63.81 1* 50.0001
Number of involved nodes
0 118
1–2 58
3–5 67
6–10 45
11+ 36 54.95 1* 50.0001
WHO predominant type
Papillary 11 23
Tubular 191 35
Mucinous 13 8
Signet-ring 17 24
Undifferentiated 76 25
Unclassiﬁed 16 24 13.18 5 0.0217
Lauren predominant type
Intestinal 205 33
Solid 22 32
Diffuse 78 19
Unclassiﬁed 19 41 6.88 3 0.0759
Mulligan predominant type
Intestinal cell 193 33
Pyloro-cardiac 19 32
Mucinous cell 31 22
Indeterminate 81 24 4.68 3 0.1972
Ming type
Expansive 151 38
Inﬁltrative 173 23 5.44 1 0.0197
Mixed Lauren types
No 221 35
Yes 103 20 6.26 1 0.0124
DIfferentiation
Good 67 44
Moderate 111 27
Poor 146 25 5.47 1* 0.0194
Tumour stroma
Unremarkable 259 28
Heavy lymphocytic inﬁltrate 65 38 4.26 1 0.0390
Eosinophils
Absent 133 23
Scanty 167 31
Numerous 24 62 6.36 1* 0.0117
*Indicates a logrank test for trend.
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Patient characteristics
The main characteristics of the 324 patients included in this analy-
sis are shown in Table 1. Two-thirds of the patients are male, 40%
were over 70 years old and nearly half had an antral tumour. The
protocol advocated that patients in the D2 arm (excepting antral
tumours) should receive a distal pancreatectomy and splenectomy,
which explains the imbalance in this variable. The pathological
characteristics recorded by the reference pathologist, and informa-
tion on staging, are displayed in Table 2.
Univariate survival analysis
Table 2 contains counts and 5-year survival estimates for each level
of each variable of interest. It can be seen that only Lauren predo-
minant type and Mulligan predominant type fail to achieve
signiﬁcance at the 5% level. In order to establish the combined
importance of the effects of these variables, a multivariate approach
was used.
Multivariate survival analysis
The results of the model ﬁtting procedure can be seen in
Table 3. As in the univariate analysis, all of the variables
except predominant Lauren type and predominant Mulligan
type were signiﬁcant when added into the initial model.
Again clinical stage is the most important prognostic factor.
When clinical stage was adjusted for, only extent of eosino-
philic inﬁltration had a signiﬁcant independent effect.
Survival curves by clinical stage and eosinophil level are
shown in Figures 1 and 2.
Hazard ratios, with 95% conﬁdence intervals, for the signiﬁ-
cant variables are tabulated in Table 4. Stage II patients have
double the risk of death as stage I patients, and for stage III
patients the risk is increased to 3.5 times that for stage I. A high
level of eosinophils was associated with less than half the risk of
death of those who have no eosinophils, however it should be
noted that the group of patients with a high level of eosinophils
is very small. The association between improved survival and a
high eosinophil count is repeated for all stages, as can be seen
in Figure 3.
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Table 3 Test statistics and P-values for Cox model ﬁt
Number of variables present in model
012
Variable added Statistic P-value Statistic P-value Statistic P-value
Clinical stage 65.24 50.001 Included Included
Number of involved nodes 55.69 50.001 7.00 0.136
T stage 44.82 50.001 3.14 0.208 2.30 0.316
N stage 39.70 50.001 1.69 0.430 1.23 0.540
Eosinophils 7.39 0.025 7.11 0.029 Included
Mixed Lauren types 6.25 0.012 0.61 0.434 0.29 0.588
Ming type 5.43 0.020 0.52 0.469 0.33 0.568
Predominant WHO type 13.17 0.022 6.10 0.296 6.11 0.295
Tumour stroma 4.26 0.039 0.84 0.359 0.93 0.335
Differentiation 6.02 0.049 1.47 0.479 1.21 0.546
Predominant Lauren type 6.87 0.076 0.70 0.873 1.70 0.636
Predominant Mulligan type 4.67 0.198 0.70 0.873 0.50 0.919
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1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Events Total
I 57 103
II 64 81
III 131 140
01234567
Years
Patients at risk   (Events)
I 103 (19) 84 (8) 75 (7) 68 (3) 60 (3) 50 (3) 39 (2) 33
II 81 (26) 55 (12) 41 (11) 29 (4) 23 (5) 17 (2) 14 (1) 11
III 140 (62) 78 (39) 39 (12) 26 (9) 17 (3) 14 (1) 10 (0) 8
Figure 1 Survival by clinical staging.
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1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
01234567
Years
Patients at risk   (Events)
Absent 133 (52) 81 (27) 54 (12) 40 (4) 34 (6) 26 (1) 21 (0) 17
Scanty 167 (52) 115 (29) 83 (17) 66 (10) 52 (5) 42 (4) 31 (3) 25
Numerous 24 (3) 21 (3) 18 (1) 17 (2) 14 (0) 13 (1) 11 (0) 10
Events Total
Absent 107 133
Scanty 129 167
Numerous 16 24
Figure 2 Survival by eosinophil level.
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inﬁltration is shown in Table 5. There was no signiﬁcant correla-
tion between these variables (w
2 statistic=2.89, P=0.24 on 2 d.f.).
Table 6 shows the pathological variables divided by clinical
stage. This table gives an indication of why the signiﬁcant effect
of these variables detected on univariate analysis was not found
in the multivariate analysis once clinical stage had been added into
the model. For example, Table 2 suggests that patients with expan-
sive Ming type have better survival than those with inﬁltrative type.
It can be seen in Table 6 that 32% of expansive patients are stage
III whereas 53% of inﬁltrative patients are stage III, thus ensuring
lower survival for inﬁltrative patients. This pattern is repeated for
many of the pathological variables.
DISCUSSION
A detailed review published in 1995 (Hermanek et al, 1995)
concluded that all large multivariate studies in gastric cancer ﬁnd
tumour stage and nodal status to have a signiﬁcant prognostic
inﬂuence, but the role of other variables is less clear. Apparent
differences in prognosis for different WHO or Lauren sub-types
are usually explained by particular sub-types being associated with
more advanced disease.
Subsequent to the review by Hermanek et al (1995), there have
been several conﬂicting reports on the relationship between histo-
logical variables and survival. An Estonian study of 406 patients
treated by radical gastrectomy found in a multivariate analysis that
in addition to stage, nodal status, extent of gastrectomy and age;
papillary, tubular and undifferentiated tumours offered better
survival (Arak and Kull, 1994). A study of 895 Spanish patients
found a survival beneﬁt for patients with intestinal Lauren type
(Jimeno-Aranda et al, 1996), although this study included stage
IV patients, whereas a small Swedish study of 88 patients found
a beneﬁt for diffuse Lauren type in a univariate analysis (Athlin
et al, 1996). A population-based study of 325 patients from France
reported that along with age, tumour stage, nodal status, presence
of metastases, site and gross type, Ming’s inﬁltrative type was asso-
ciated with lower survival in a multivariate analysis (Roy et al,
1998). In a Japanese series of 195 patients who received curative
resection a survival beneﬁt was demonstrated in a multivariate
model for well-differentiated tumours together with number of
involved nodes and depth of invasion (Adachi et al, 1994). Well-
differentiated tumours were also associated with improved survival
in a study of 3926 patients from South Korea. They were included
in a multivariate model with tumour stage, nodal status, gross type
and location (Kim et al, 1994).
A prospective Japanese study of 647 patients (Iwasaki et al,
1986) found a signiﬁcant difference in 5-year survival (57 vs 39%
in advanced cases) between patients with more or less than 100
eosinophils inﬁltrating the tumour. In the MRC study, tumour
stage, nodal status, clinical stage, WHO predominant type, Lauren
predominant type, Ming type, Lauren mixed type, differentiation,
tumour stroma and eosinophilic inﬁltration were all signiﬁcant at
the 5% level in the univariate analysis. However, when a multivari-
ate survival model was chosen, only eosinophils had a signiﬁcant
effect once clinical stage was included in the model. Thus any
apparent beneﬁt for a particular histological subtype would appear
to be explained by that subtype being associated with less advanced
disease. A study based on a subset of patients entered into the
Dutch gastric cancer surgical trial found on univariate analysis, that
the amount of both lymphocytic and eosinophilic inﬁltration were
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Table 4 Hazard ratios for signiﬁcant variables in the multivariate model
95% conﬁdence
Hazard ratio interval
Clinical stage I 1
II 2.04 (1.42–2.92)
III 3.47 (2.52–4.79)
Eosinophils Absent 1
Scanty 0.88 (0.68–1.14)
Numerous 0.49 (0.29–0.84)
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1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
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Events Total
I2 3 3 8
II 29 55
III 5 10
01234567
Years
Patients at risk   (Events)
I 38 (9) 29 (5) 24 (4) 20 (0) 19 (1) 17 (1) 14 (0) 12
II 55 (9) 46 (3) 42 (2) 40 (3) 34 (2) 27 (2) 20 (2) 17
III 10 (1) 9 (0) 9 (1) 8 (0) 7 (0) 6 (0) 5 (0) 4
01234567
Years
Patients at risk   (Events)
I 31 (10) 21 (4) 17 (4) 12 (2) 9 (3) 5 (0) 4 (0) 3
II 43 (15) 28 (7) 19 (7) 12 (2) 9 (2) 7 (1) 6 (1) 4
III 7 (1) 6 (1) 5 (0) 5 (0) 5 (0) 5 (1) 4 (0) 4
Events Total
I2 4 3 1
II 35 43
III 5 7
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0.9
0.8
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0.6
0.5
0.4
0.3
0.2
0.1
0.0
Events Total
I6 0 6 4
II 65 69
III 6 7
01234567
Years
Patients at risk   (Events)
I 64 (33) 31 (18) 13 (4) 8 (2) 6 (2) 4 (0) 3 (0) 2
II 69 (28) 41 (19) 22 (8) 14 (5) 9 (1) 8 (1) 5 (0) 4
III 7 (1) 6 (2) 4 (0) 4 (2) 2 (0) 2 (0) 2 (0) 2
I
II
III
Figure 3 Survival by eosinophil level (stages I–III).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 674–679of signiﬁcant prognostic value (eight patients). Along with TNM
stage, marked lymphocytic inﬁltration was also associated with
better survival in multivariate analysis. However, only 105 out of
996 eligible patients were included in this analysis.
One of the difﬁculties of determining whether a high level of
eosinophilic inﬁltration inﬂuences survival in gastric cancer is that
the extent of eosinophil stromal inﬁltration has not been standar-
dized. In the present study based on the MRC trial, as well as those
described by Yu et al (1995) and Songun et al (1996), eosinophil
inﬁltration has been graded into three groups: none or few, moder-
ate or scanty, marked or numerous. Only Iwasaki et al (1986)
described a more objective index: none, 5100 cells, 4100 cells.
The subjectivity of these deﬁnitions can lead to a high level of
inter-observer variation in assessments by different pathologists.
This is best demonstrated by Yu’s study (Yu et al, 1995), where
eosinophils graded by one pathologist had a signiﬁcant effect on
survival whereas the assessments of the other review pathologist
were not found to be signiﬁcant. We could not validly assess the
inter-observer variation in the present study as only one reference
pathologist examined the majority of the pathological slides.
Undoubtedly this is a weakness of the present study.
Tumour stromal eosinophilic inﬁltration has also been docu-
mented and investigated in a study of 38 early gastric cancers
(EGC). In this study electron microscopy showed tumour stromal
eosinophils with morphological evidence of activation and some
tumour cells in intimate contact with activated eosinophils exhib-
ited focal cytopathic changes (Caruso et al, 1993). Gastric
carcinomas have been shown to express eosinophil chemotactic
cytokines including IL-2, IL-5 and GM–CSF and expression of
GM–CSF appears to be speciﬁc for signet ring carcinoma cells
(Hong et al, 1999).
An early report in 1983 from the Cleveland clinic on 67 colorectal
carcinomas reported great variability in the number of eosinophils in
histological sections of the tumours but demonstrated a positive
correlation between the numbers of stromal eosinophils and survival
time (Pretlow et al, 1983). Two recent larger reports on stromal eosi-
nophilic inﬁltration of colorectal cancer document a similar
beneﬁcial effect on prognosis (Nielsen et al, 1999; Fernandez-Acenero
et al, 2000). The improved prognosis associated with the presence of
marked tumour-associated tissue eosinophilia (TATE) in two cancers
at either end of the gut is interesting and merits further investigation
even if this is only found in a small percentage (8% in the present
study) of these gastrointestinal cancers. Abnormal recruitment of
tissue eosinophils is encountered in a variety of medical conditions
including speciﬁc malignancies e.g., Hodgkin’s disease certain types
of leukaemia (Ogata et al, 1998) and some solid tumours (Pretlow
et al, 1983; Iwasaki et al, 1986; Bethwaite et al, 1993; Caruso et al,
1993; Yu et al, 1995; Leighton et al, 1996; Songun et al, 1996; Ono
et al, 1997; Geisinger et al, 1998; Tajima et al, 1998; Hong et al,
1999; Nielsen et al, 1999; Moezzi et al, 2000). TATE may simply be
a surrogate marker of a distinctive cytokine response to an inﬁltrative
tumour. Alternatively TATE may indicate an unusual anti-tumour
immune response. Th1 and Th2 reactions involve a variety of cell
types. In general, type 1 cytokines induce a strong cellular immune
response whereas type 2 cytokines, predominantly a humoral
response. The two systems cross regulate each other. Type 2 cytokines
(IL-4 and IL-5) are known to attract eosinophilic granulocytes and
for this reason, TATE may reﬂect a combination of strong type 2
and weak type 1 responses (van Driel et al, 1996). Experiments on
the effector phase of tumour rejection induced by vaccination with
irradiated tumour cells indicate that immunisation leads to simulta-
neous induction of Th1 and Th2 responses (Hung et al, 1998).
Cytokines produced by CD4(+) T cells activate eosinophils and
macrophages and these may be responsible for direct tumour cell
destruction. Tumour inﬁltrating eosinophils may also modulate
angiogenesis and desmoplastic reaction (Ono et al, 1997; Samoszuk,
1997). Eotaxin is the most researched C-C chemokine (Fankin et al,
2000), its human gene has been characterized and shown to be an
early response gene of cytokine-stimulated epithelial and endothelial
cells (Garcia-Zepeda et al, 1996). It may provide the molecular basis
for eosinophil recruitment in certain tumours especially of the
gastrointestinal tract.
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Table 5 Eosinophilic inﬁltration by lymphocytic inﬁltration
Lymphocytic inﬁltration
Unremarkable Heavy inﬁltrate Total
n (%) n (%) n (%)
Eosinophils
Absent 108 (42) 25 (38) 133 (41)
Scanty 135 (52) 32 (49) 167 (52)
Numerous 16 (6) 8 (12) 24 (7)
Total 259 65 324
Table 6 Pathological classiﬁcations by clinical stage
Stage I Stage II Stage III
n (Row %) n (Row %) n (Row %)
WHO predominant type
Papillary 7 (64) 3 (27) 1 (9)
Tubular 72 (38) 54 (28) 65 (34)
Mucinous 2 (15) 3 (23) 8 (62)
Signet-ring 4 (24) 3 (18) 10 (59)
Undifferentiated 13 (17) 14 (18) 49 (64)
Unclassiﬁed 5 (31) 4 (25) 7 (44)
Lauren predominant type
Intestinal 81 (40) 56 (27) 68 (33)
Solid 5 (23) 6 (27) 11 (50)
Diffuse 10 (13) 15 (19) 53 (68)
Unclassiﬁed 7 (37) 4 (21) 8 (42)
Mulligan predominant type
Intestinal cell 80 (41) 51 (26) 62 (32)
Pyloro-cardial 5 (26) 5 (26) 9 (47)
Mucous cell 5 (16) 8 (26) 18 (58)
Indeterminate 13 (16) 17 21 51 (63)
Ming type
Expansive 65 (43) 38 (25) 48 (32)
Inﬁltrative 38 (22) 43 (25) 92 (53)
Mixed Lauren types
No 82 (37) 61 (28) 78 (35)
Yes 21 (20) 20 (19) 62 (60)
Differentiation
Good 38 (57) 18 (27) 11 (16)
Moderate 39 (35) 30 (27) 42 (38)
Poor 26 (18) 33 (23) 87 (60)
Tumour stroma
Unremarkable 80 (31) 57 (22) 122 (47)
Heavy lymphocytic inﬁltrate 23 (35) 24 (37) 18 (28)
Eosinophils
Absent 38 (29) 31 (23) 64 (48)
Scanty 55 (33) 43 (26) 69 (41)
Numerous 10 (42) 7 (29) 7 (29)
Total 103 81 140
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